OTTAWA, April 19 /CNW/ - Nine leading Canadian radiation oncologists are
exploring next generation enhancements to prostate cancer treatment
with support from Abbott Oncology's ACURA Uro-Oncologic Radiation
Awards. A selection committee of members of the Canadian Association of
Radiation Oncology (CARO-ACRO) selected the 2011 recipients from among
a field of 34 applicants.
Dr. Gerard Morton, committee chair, explains, "The ACURA Award program
provides a unique and highly valued source of seed funding for basic
science, translational, clinical and population-based prostate cancer
research. A total of 93 Canadian projects have been funded in the past
Examples of the 2011 research initiatives include:
Dr. Nawaid Usmani of Edmonton's Cross Cancer Institute is exploring the use of genetic
information to identify aggressive cancers when patients are first
diagnosed, in order to help guide doctors in choosing the most
effective treatments for their patients.
Dr. Eric Vigneault of CHUQ and Hôtel-Dieu de Québec is examining the impact of delayed
wait times in the treatments of patients with intermediate and
high-risk prostate cancer. The retrospective study will evaluate how
patient outcomes are affected by the amount of time between prostate
biopsy and treatment.
Dr. John Amanie of the University of Alberta is studying the targeted use of gold
nanoparticles to enhance the tumor killing effect of radiation therapy
on prostate cancer cells. The goal is to improve cure rates, while
minimizing side effects on surrounding tissues near the prostate gland.
Dr. Cynthia Menard of Toronto's Princess Margaret Hospital is developing a new PET scan
for patients with prostate cancer that will help to guide and tailor
radiation treatments based on the oxygen properties of each patient's
Dr. George Rodrigues of London Health Sciences Centre is creating the Prostate Cancer Risk
Stratification database, which will provide Canadian cancer researchers
with an unparalleled opportunity to define risk categories and
treatment outcomes for prostate cancer patients.
Other award recipients include: Dr. Julie Bowen, Regional Cancer Program, Sudbury Regional Hospital; Dr. Hans Chung, Odette Cancer Centre; Dr. Laura D'Alimonte, Odette Cancer Centre; and, Dr. Raffi Karshafian, Ryerson University & Odette Cancer Centre.
"These awards are critical to the radiation oncology profession in
Canada," says Dr. Morton, "enabling our members to continue to break
new ground in the successful treatment and cure of prostate cancer."
Full details of the $200,000 in financial awards made to the nine 2011
recipients are available in a separate chart, posted on the CARO-ACRO
web site: www.caro-acro.ca
About the Canadian Association of Radiation Oncology
Canadian Association of Radiation Oncology (CARO) - Association
canadienne de radio-oncologie (ACRO) is a not-for-profit association
with the mandate to represent and support its membership nationally and
internationally, through the promotion of high standards of patient
care in the practice of radiation oncology, support of excellence in
professional standards, and promotion of radiation oncology research
CARO is a partner with other disciplines in seeking to improve outcomes
for cancer patients, and provides a consultative authority to oncology
related agencies, academic institutions, and to the public in all
matters pertaining to radiotherapy and oncology in Canada. For further
Abbott is a global, broad-based health care company devoted to the
discovery, development, manufacture and marketing of pharmaceuticals
and medical products, including nutritionals, devices and diagnostics.
The company employs nearly 90,000 people and markets its products in
more than 130 countries. Abbott has been operating in Canada since 1931
and its Canadian operations are headquartered in Montreal, Quebec.
Abbott Canada employs more than 2,000 people. Abbott's news releases
and other information are available on the company's web sites at www.abbott.ca and www.abbott.com.
SOURCE Canadian Association of Radiation Oncology
For further information:
J. McLarty, email@example.com or 604.740.5839